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Abstract
In LACOG 0801 phase II study 142 patients with HER2D MBC with progression after taxane were randomized
between Lapatinib (L) combined with Capecitabine (C), Vinorelbine (V) or Gemcitabine (G). ORR was 49% in LC,
56% in LV and 41% in LG group. The overall toxicity was manageable in all regimens.
Background: Novel targeted agents and combinations have become available in multiple lines of treatment for
human epidermal growth factor receptor 2-positive (HER2þ) metastatic breast cancer (MBC). In this context,
alternatives to the lapatinib (L) and capecitabine (C) regimen, evaluating L combined with other cytotoxic drugs,
are warranted. Patients and Methods: In the present phase II, multicenter study, patients with HER2þ MBC with
progression after taxane were randomized between L, 1250 mg, combined with C, 2000 mg/m2 on days 1 to 14
(LC), vinorelbine (V), 25 mg/m2 on days 1 and 8 (LV), or gemcitabine (G), 1000 mg/m2 on days 1 and 8 (LG), every
21 days. The primary endpoint was the overall response rate. Results: A total of 142 patients were included from
2009 to 2012. No differences were found in the patient baseline characteristics. The median age was 51 years,
69% were postmenopausal, 32% had liver metastasis, 57% were hormone receptor negative, and 48% had
been previously treated with trastuzumab. The overall response rate was 49% (95% conﬁdence interval [CI],
34.8%-63.4%), 56% (95% CI, 40%-70.4%), and 41% (95% CI, 27%-56.8%) in the LC, LV, and LG groups,
respectively. The median progression-free survival was 9 months in the LC arm and 7 months in the other 2 arms
(P ¼ .28). The most common grade 3 and 4 adverse events were hand-foot syndrome (18%), diarrhea (6%), and
increased alanine aminotransferase/aspartate aminotransferase (4%) in the LC arm; neutropenia (36%), diarrhea1Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
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(9%), and febrile neutropenia (6%) in the LV arm; and neutropenia (47%), alanine aminotransferase/aspartate
aminotransferase (13%), and rash (4%) in the LG arm. Conclusion: LV and LG seem to be active combinations in
patients with HER2þ MBC after taxane failure. The overall toxicity was manageable in all regimens.
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outcomeIntroduction
The human epidermal growth factor receptor 2 (HER2) is a
potent mediator of cellular growth and proliferation.1 Ampliﬁcation
of the HER2 gene, and the corresponding overexpression of HER2
occur in approximately 20% of breast tumors and are associated
with a poor outcome.2 Molecular targeting of the HER2 with the
humanized monoclonal antibody trastuzumab (Herceptin; Gen-
entech, San Francisco, CA) has improved the disease-free and
overall survival of patients with both metastatic breast cancer
(MBC) and early-stage HER2þ breast cancer.2-6
Lapatinib (L) (Tykerb; GlaxoSmithKline, Brentford, UK) is a
small molecule dual kinase inhibitor of HER2 and epidermal
growth factor receptor that showed beneﬁt in terms of the time to
progression for use when combined with capecitabine (C) for the
treatment of patients with MBC with progression after or during
previous therapy, including an anthracycline, a taxane, and tras-
tuzumab.7 The positive results obtained with the LC regimen
support the evaluation of L combined with other cytotoxic drugs,
especially for an alternative because of the multiple lines of
therapy for HER2þ disease available currently. However, the
potential for overlapping toxicity raises the question of whether L
can be combined with different chemotherapy agents for patients
with anthracycline- and taxane-resistant disease.
Vinorelbine (V) is a vinca alkaloid that has been evaluated as a single
agent and when combined with various cytotoxic agents in numerous
studies for the treatment of MBC.8 In HER2þ breast cancer cell lines,
preclinical studies have demonstrated synergistic activity with trastu-
zumab. Anumber of studies have suggested that the LV combination is
effective and safe for patients with HER2þ recurrent or MBC.9-12
Gemcitabine (G) is a nucleoside metabolic inhibitor that kills
cells undergoing DNA synthesis and blocks the progression of cells
through the G1/S-phase boundary. As a single agent, G is active in
second- and third-line treatment for patients with MBC. G, com-
bined with paclitaxel, is indicated for ﬁrst-line treatment after failure
of previous anthracycline-containing adjuvant chemotherapy.13
Although some studies have shown activity with G combined
with trastuzumab, no evaluation has been performed of the com-
bination of G with L in patients with pretreated HER2-
overexpressing MBC.14-16
The aim of the present study was to evaluate potential L
chemotherapy combinations as ﬁrst- and/or second-line treatment
in HER2þ MBC progressing after taxane use.
Patients and Methods
Patients
The eligible patients were female, aged > 18 years, with histo-
logically conﬁrmed locally advanced or metastatic invasiveadenocarcinoma of the breast with an Eastern Cooperative
Oncology Group 0 to 2 and HER2þ (immunohistochemistry 3þ or
a positive score by ﬂuorescence in situ hybridization tested by a local
laboratory). The subjects were required to have developed pro-
gression after previous therapy with taxanes, have a maximum of 1
previous chemotherapy regimen for metastatic disease, and have
measurable disease according to the Response Evaluation Criteria In
Solid Tumors (RECIST), version 1.0. The present study was per-
formed in accordance with the Declaration of Helsinki and
approved by the local ethics committees. It was registered with
ClinicalTrials.gov (clinicaltrials.gov identiﬁer NCT01050322; trial
registration date January 14, 2010).
Study Design
The Latin American Cooperative Oncology Group (LACOG)
0801 trial was a randomized phase II, open-label, multicenter, in-
ternational, 3-arm study. The patients were randomized to receive
every 3-week cycles of L 1250 mg orally once daily continuously
plus C 2000 mg/m2/day orally in 2 doses on days 1 to 14 (LC arm);
L at the same dose plus V 25 mg/m2/day intravenously on days 1
and 8 (LV arm); or L at the same dose plus G 1000 mg/m2 on days
1 and 8 (LG arm). The patients were stratiﬁed by previous treat-
ment with trastuzumab (yes vs. no), previous taxane therapy in the
neoadjuvant or adjuvant setting (yes vs. no), and the presence of
liver metastases (yes vs. no).
The patients received randomized study treatment until disease
progression or unacceptable toxicity, withdrawal of consent, loss to
follow-up, or death. An interim safety analysis was conducted by an
independent data monitoring committee after enrollment of the ﬁrst
83 patients (LC, n ¼ 29; LV, n ¼ 28; LG, n ¼ 26), which allowed
for continuation of the present study.
Assessment
Response of Target Lesions. The primary endpoint was the overall
response rate (ORR), deﬁned as the percentage of patients experiencing
a conﬁrmed complete response (CR) or partial response (PR).
The secondary endpoints included progression-free survival
(PFS), overall survival (OS), and duration of response (DoR). PFS
was deﬁned as the time from randomization to the time of ﬁrst
documented disease progression at any site or death from any cause.
OS was deﬁned as the time from randomization until death from
any cause. The DoR was deﬁned as the time from the ﬁrst docu-
mented evidence of a CR or PR until the ﬁrst documented sign of
disease progression or death from any cause.
The tumor response was assessed using the RECIST, version
1.0.17 The patients underwent disease assessments at screening,
every 9 weeks for the ﬁrst 9 cycles, and then every 12 weeks untilClinical Breast Cancer February 2016 - 39
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40 -progression. After progression, the patients were interviewed every
12 weeks to collect the disease status and survival data. Computed
tomography and magnetic resonance imaging were the preferred
methods of measuring the target lesions. Bone scans were indi-
cated for patients with bone metastasis and were repeated every 24
weeks.
Safety. Safety information was obtained from all the study pa-
tients. The data included the laboratory values and adverse events
(AEs) and other signs and symptoms, which were graded according
to the National Cancer Institute Common Terminology Criteria for
Adverse Events, version 3.0. The safety evaluations were scheduled
at the beginning of each treatment cycle and  30 days after the last
dose of study drug. Patients with treatment-related toxicities were
followed up continuously during treatment and every 30 days after
withdrawal of treatment until resolution.
Statistical Analysis
The LC regimen for MBC has been reported to have an ORR
of 22%.7 The sample size was determined according to 80%
power to detect an ORR of 22%  12% (95% conﬁdence in-
terval [CI], 10%-34%) and a signiﬁcant difference at the 1-sided
5% level. Assuming a withdrawal rate of 10%, the study would
have needed to enroll  45 patients in each treatment arm (n ¼
135 patients). The present study was not powered to detectFigure 1 Latin American Cooperative Oncology Group 0801 Trial Co
Clinical Breast Cancer February 2016differences between the combinations; hence, no hypothesis
testing was performed.
The primary analysis of efﬁcacy was performed in response-
evaluable patients. The ORR for each treatment group was
compared using the Cochran-Mantel-Haenszel test stratiﬁed by the
presence of liver metastases, previous trastuzumab use, and the use
of taxanes. PFS was estimated using the Kaplan-Meier method and
compared using the log-rank test. Clinical safety and tolerability
were assessed in the safety population, which included all patients
who had received  1 doses of study medication.
Results
Patient Characteristics
The trial proﬁle is shown in Figure 1. A total of 142 patients
from Argentina, Brazil, and Peru were included from 2009 to 2012.
The patient baseline characteristics were well balanced among the 3
arms (Table 1), with the exception that patients in the LG arm
were younger and had more concomitant visceral and nonvisceral
disease, and a greater proportion had received previous chemo-
therapy for metastatic disease. The median age was 51 years, 69%
were postmenopausal, and 97% had an Eastern Cooperative
Oncology Group performance status of 0 to 1. Liver metastases
were present in 32% of patients, 71% had received taxanes as
neoadjuvant or adjuvant treatment, and 48% had received previous
trastuzumab.nsort Diagram
Table 1 Patient Baseline Characteristics
Characteristic LC (n [ 51) LV (n [ 45) LG (n [ 46) Total (n [ 142)
Age (years)
Median 52 55 43 51
Range 32-70 26-84 20-72 20-84
Performance status (ECOG)
0-1 49 (96) 44 (98) 45 (98) 138 (97)
2 2 (4) 1 (2) 1 (2) 4 (3)
Time since initial diagnosis (mo)
Median 21 21 21 21
Range 1-208 1-103 0-132 1-208
Postmenopausal 39 (76) 34 (75) 26 (57) 99 (69)
HER2 status
IHC 3þ 47 (92) 42 (93) 42 (91) 131 (92)
IHC 2þ FISH/CISH positive 3 (6) 3 (7) 3 (7) 9 (6)
FISH/CISH positive 1 (2) 0 1 (2) 2 (2)
Hormone receptor
ER and/or PR positive 23 (45) 17 (38) 21 (45) 61 (43)
ER and PR negative 28 (55) 28 (62) 25 (55) 81 (57)
Stage at diagnosis
0 1 (2) 1 (2) 2 (4) 4 (3)
I 1 (2) 2 (4) 3 (7) 6 (4)
IIA-IIB 15 (29) 11 (24) 9 (20) 35 (25)
IIIA-IIIC 26 (51) 28 (62) 22 (48) 76 (53)
IV 8 (16) 3 (7) 10 (22) 21 (15)
Liver metastasis 18 (35) 13 (29) 15 (33) 46 (32)
Previous chemotherapy for MBC 22 (43) 23 (51) 29 (63) 74 (52)
Previous trastuzumab treatment 25 (49) 21 (47) 24 (52) 68 (48)
Data presented as n (%), unless otherwise noted.
Abbreviations: CISH ¼ chromogenic in situ hybridization; ECOG ¼ Eastern Cooperative Oncology Group; ER ¼ estrogen receptor; FISH ¼ ﬂuorescence in situ hybridization; HER2 ¼ human
epidermal growth factor receptor 2; IHC ¼ immunohistochemistry; LC ¼ lapatinib and capecitabine; LG ¼ lapatinib and gemcitabine; LV ¼ lapatinib and vinorelbine; MBC ¼ metastatic breast
cancer; PR ¼ progesterone receptor.
Henry L. Gómez et alTreatment Exposure
The median number of cycles per patient was 7 (range, 1-42)
in the LC arm, 7 (range, 1-25) in the LV arm, and 6 (range, 1-Table 2 Summary of Efﬁcacy Results (ITT Population)
Variable
LC
(n [ 51)
LV
(n [ 45)
LG
(n [ 46)
Total
(n [ 142)
Best response
CR 5 (10) 5 (11) 1 (2) 11 (8)
PR 21 (41) 19 (42) 17 (37) 57 (40)
SD 11 (22) 9 (20) 17 (37) 37 (26)
PD 6 (12) 6 (13) 4 (9) 16 (11)
NE 8 (16) 6 (13) 7 (15) 21 (15)
ORR 25 (49) 25 (56) 19 (41) 69 (49)
95% CI 34.8-63.4 40-70.4 27-56.8 40.1-57.1
Data presented as n (%), unless otherwise noted.
Fisher’s exact test, P ¼ .3631.
Abbreviations: CI ¼ conﬁdence interval; CR ¼ complete response; ITT ¼ intention to treat;
NE ¼ not evaluable; ORR ¼ objective response rate; PD ¼ progressive disease; PR ¼ partial
response; SD ¼ stable disease.27) in LG arm. Of the 142 patients randomized, 141 had
received  1 doses of study therapy, and 36 (26%) had dis-
continued study treatment before disease progression: 14 (27%)
in the LC, 9 (20%) in the LV, and 13 (29%) in the LG arm.
AEs led to treatment discontinuation in 11 patients (22%) in
the LC arm, 5 (11%) in the LV arm, and 12 (27%) in the LG
arm.
Efﬁcacy
The ORR in the total study population was 48.5% (95% CI,
40.1%-57.1%). The best response and ORR per arm are listed in
Table 2. No statistically signiﬁcant differences were found in the
ORR among the 3 L-based regimens (P ¼ .33). The median
duration of response was 7 months (95% CI, 5.5 to 12.9 months)
in the LC arm, 4.9 months (95% CI, 3.9 to 8.1 months) in the LV
arm, and 4.9 months (95% CI, 2.8 to 8.1 months) in the LG arm
(P ¼ .24).
The median PFS was 9 months in the LC arm and 7 months in
the other 2 arms (P ¼ .28; Figure 2). Of the 142 patients, 80
(56.3%) had died at the OS analysis. The median OS was 19.6
months (95% CI, 12.7-30.2 months; 51% of the events) in the LCClinical Breast Cancer February 2016 - 41
Figure 2 Progression-Free Survival (PFS)
Abbreviations: CI ¼ conﬁdence interval; LC ¼ lapatinib and capecitabine; LG ¼ lapatinib and gemcitabine; LV ¼ lapatinib and vinorelbine
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42 -arm, 15 months (95% CI, 9.4-22.4 months; 60% of events) in the
LV arm, and 11.9 months (95% CI, 9.3-17.1 months; 59% of
events) in the LG arm (P ¼ .20).Table 3 Most Common Treatment-Related Adverse Events, Occurrin
AE
LC (n [ 51)
All Grades Grade 3 Grade 4 All Grades
Neutropenia 7 (14) 0 0 24 (53)
Leukopenia 3 (6) 0 0 3 (7)
Anemia 9 (18) 1 (2) 0 16 (36)
ALT increase 6 (12) 2 (4) 0 8 (18)
AST increase 10 (20) 1 (2) 0 6 (13)
Bilirubin increase 19 (37) 1 (2) 0 4 (9)
Diarrhea 35 (68) 3 (6) 0 30 (67)
Nausea 15 (29) 1 (2) 0 13 (29)
Vomiting 10 (20) 1 (2) 0 9 (20)
Mucositis 18 (35) 1 (2) 0 7 (16)
Anorexia 8 (16) 0 0 6 (13)
Asthenia 4 (8) 1 (2) 0 3 (7)
Hand-foot syndrome 29 (57) 11 (22) 1 (2) 1 (2)
Rash 6 (12) 2 (4) 0 2 (4)
Acne 5 (10) 0 0 2 (4)
Paronychia 8 (16) 1 (2) 0 4 (9)
Pain in extremities 2 (4) 0 0 7 (16)
Phlebitis 0 0 0 6 (13)
Abdominal pain 3 (6) 1 (2) 0 3 (7)
Data presented as n (%).
Abbreviations: AEs ¼ adverse events; ALT¼ alanine aminotransferase; AST ¼ aspartate aminotransferase;
Clinical Breast Cancer February 2016In an exploratory analysis, we evaluated the ORR and PFS ac-
cording to the previous use of trastuzumab. In the overall popula-
tion, patients with no previous trastuzumab use had an ORR ofg in ‡ 10% of Patients (Safety Population)
LV (n [ 45) LG (n [ 45)
Grade 3 Grade 4 All Grades Grade 3 Grade 4
12 (27) 4 (9) 30 (67) 17 (38) 4 (9)
1 (2) 0 7 (15) 3 (7) 0
1 (2) 0 15 (33) 1 (2) 0
2 (4) 0 18 (40) 6 (13) 0
2 (4) 0 15 (33) 5 (11) 0
1 (2) 0 6 (13) 1 (2) 0
4 (9) 0 28 (62) 1 (2) 0
1 (2) 0 17 (38) 1 (2) 0
1 (2) 0 6 (13) 0 0
2 (4) 0 5 (11) 0 0
0 0 10 (22) 0 0
2 (4) 0 13 (29) 1 (2) 0
0 0 4 (9) 1 (2) 0
0 0 11 (24) 2 (4) 0
0 0 9 (20) 0 0
0 0 7 (16) 0 0
0 0 0 0 0
0 0 0 0 0
0 0 5 (11) 0 0
LC ¼ lapatinib and capecitabine; LG¼ lapatinib and gemcitabine; LV ¼ lapatinib and vinorelbine.
Henry L. Gómez et al55.5% (95% CI, 43.4%-67.3%) versus 41.4% (95% CI,
29.8%-53.8%) for those who had received trastuzumab. The cor-
responding PFS was 6.2 months (95% CI, 4.5-7.8 months) and 5.9
months (95% CI, 4.3-7.6 months; P ¼ .99).
Safety
A total of 141 randomized patients received  1 dose of the study
treatment and were included in the safety population. One ran-
domized patient in the LG arm had withdrawn informed consent
before receiving the ﬁrst treatment dose.
Of the 141 patients, 140 (99.3%) reported  1 AE. The most
common treatment-related AEs are listed in Table 3. The 3 most
frequent treatment-related AEs in each treatment group were diar-
rhea (69%), hand-foot syndrome (57%), and nausea (29%) in the
LC arm; diarrhea (67%), neutropenia (53%), and anemia (36%) in
the LV arm; and diarrhea (62%), neutropenia (67%), and nausea
(38%) in the LG arm. Most AEs were grade 1 or 2 in severity.
A total of 46 patients (32.6%) experienced  1 serious AE: 15
(29.4%) in the LC arm, 17 (37.7%) in the LV arm, and 14 (31.1%) in
the LG arm. The most common serious AEs were sepsis (4%; 2% in
the LC, 7% in the LV, and 2% in the LG arms), febrile neutropenia
(3%; 2% in the LC, 7% in the LV, and 0% in the LG arm), deep vein
thrombosis (3%; 2% in the LC, 4% in the LV, and 2% in the LG
arm), and diarrhea (3%; 6% in the LC, 0% in the LV, and 2% in the
LG arm). Three patients (2%) died of AEs; 1 in the LV arm developed
sepsis related to treatment, and 1 patient each in the LG arm devel-
oped sepsis and pneumonia, considered not related to the study drugs.
Discussion
In the evolving scenario of new drugs and regimens for the
treatment of metastatic HER2þ breast cancer, the exploration of L
and other chemotherapy combinations is warranted. In the present
randomized phase II trial, we evaluated the efﬁcacy and safety of
new combinations of L with V or G and in the standard regimen
with C. Although limited data are available regarding the combi-
nation of L and V, to our knowledge, this is the ﬁrst study testing
the combination of L and G in this setting.
The response rates and safety proﬁle observed, especially in the
experimental arms, in our heterogeneous population, including
some patients with trastuzumab-resistant disease, are encouraging.
The ORR for the entire study population was 48.5%, with no
signiﬁcant difference observed among the 3 treatment arms (P ¼
.33). The combination of L with C resulted in an ORR of 49%
(95% CI, 34.8%-63.4%), which compares with an ORR of 11.1%-
51.9% in the published data.7,18-22 The ORR was 56% for V (95%
CI, 40%-70.4%), in the upper range of previously published data
(20%-40%) for V combined with L.9,11,12 Response rates of 51% to
59.3% were reported when combining V, in different doses, with
trastuzumab.23,24 The LG arm had an ORR of 41% (95% CI,
27%-56.8%), comparable to previously published data for the
combination of G with trastuzumab (30%-62%).14,15,25 A case
report of the LG combination in a patient with MBC resistant to
trastuzumab showed a complete CR that lasted for 1 year.16 In an
exploratory analysis of our trial, we did not ﬁnd a difference in terms
of ORR and PFS when comparing patients who had or had not
received previous trastuzumab. The median PFS was 9 months inthe LC arm and 7 months in the other 2 arms. The median OS was
19.6 months in the LC arm and 15.6 months in the LV arm. These
PFS and OS rates are well matched with those from other studies of
LC and LV in similar populations.9,11,12 The OS in the LG arm was
shorter (11.9 months) than that in the other arms, which might be
explained by the greater proportion of younger patients, hormone
receptor-negative tumors, previous treatment for metastatic disease,
and, possibly, postprogression therapy.
The overall toxicity was manageable in all 3 regimens. Diarrhea
was the most frequent AE (62%-69%) in all 3 treatment arms,
mostly lower grades, and was greater in the LC combination. These
results are similar to those from previous reports.7,9,11,12 Hand-foot
syndrome developed in 57% of patients (24% with grade 3-4) in
the LC arm. As anticipated, both the LV and the LG regimens had
lower rates (2% and 11%, respectively) of this AE. A greater degree
of bone marrow suppression was seen with LV (53%) and LG
(67%) arms than in the LC arm (14%), but febrile neutropenia was
uncommon (3%) in all 3 regimens.
Treatment discontinuation before disease progression occurred
in 26% of patients, mainly because of AEs (22% in the LC, 11%
in the LV, and 27% in the LG arms). In the pivotal LC phase III
trial, AEs led to treatment discontinuation in 13% of women
treated with the combination.7 Two studies testing the LV com-
bination had 10.7% and 15% of patients discontinuing therapy
because of AEs.11,12 Our rates were slightly greater than those
previously reported, probably owing to the strict dose reduction
and modiﬁcation rules, such as limiting the dose reduction to 50%
of the starting dose and not allowing continuation of study
treatment in the case of discontinuation of either 1 of the drugs in
each combination.
During the past years, new systemic therapies have become
available for the treatment of HER2þ MBC. The CLEOPATRA
trial established a new standard of care in ﬁrst-line therapy with
the addition of pertuzumab to trastuzumab and docetaxel, which
signiﬁcantly improved the median OS and PFS by 15.7 and 6.3
months, respectively.26 As second-line therapy, the EMILIA trial
showed that trastuzumab emtansine (T-DM1), a novel anti-
bodyedrug conjugate, signiﬁcantly prolonged PFS (9.6 vs. 6.4
months; hazard ratio [HR], 0.65; 95% CI, 0.55-0.77; P < .001)
and OS (30.9 vs. 25.1 months; HR, 0.68; 95% CI, 0.55-0.85;
P < .001) compared with the LC combination in patients with
HER2þ advanced breast cancer previously treated with trastuzu-
mab and a taxane.27 In this context, the LC combination remains
an alternative for patients in whom multiple lines of treatment
have failed.
The most recent American Society of Clinical Oncology clinical
practice guideline has recommended that for patients whose HER2þ
advanced breast cancer has progressed during or after second-line or
greater HER2-targeted treatment and who have already received
pertuzumab and T-DM1, clinicians should recommend third-line or
greater HER2-targeted treatment.28 The options include continuous
HER2 blockade with L and C and other combinations of chemo-
therapy and trastuzumab, L plus trastuzumab, or hormonal therapy
(in patients with hormone receptor-positive disease). The evidence is
insufﬁcient to recommend 1 regimen over another, and the best
sequence of regimens and how to select patients remains to beClinical Breast Cancer February 2016 - 43
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44 -determined. Although not directly addressing sequencing, our study
results suggest that alternative options exist for patients with meta-
staticHER2þ breast cancer. The combinations of LwithV and Lwith
G were associated with reasonable response rates and manageable
toxicity.
The limitations of the present study included the nonblinded
design and the low number of patients in each arm, which
compromised our ability to explore differential ﬁndings.
Conclusion
The LV and LG combinations seem to be active combinations in
patients with HER2þ MBC after taxane failure. No new safety
signals were detected with these combinations, which represent al-
ternatives to be further explored in the sequence of regimens for
patients with HER2þ breast cancer.
Clinical Practice Points
 HER2 is overexpressed in 18% to 20% of invasive breast cancer
cases, which has both prognostic and predictive implications.
 HER2 status has been shown to be predictive for the response to
HER2-targeted therapies (trastuzumab, pertuzumab, and
lapatinib).
 Lapatinib is a tyrosine kinase inhibitor of both epidermal growth
factor receptor and HER2 approved for use in combination with
capecitabine for the treatment of patients with advanced breast
cancer or MBC whose tumors overexpress HER2 and who have
received previous therapy, including an anthracycline, a taxane,
and trastuzumab.
 V and G (combinations or single-agent use) are chemotherapy
agents indicated for the treatment of recurrent breast cancer or
MBC.
 During the past years, the treatment of HER2þ breast cancer has
evolved by the development of HER2-targeted therapies, which
have been shown to improve survival in patients with metastatic
disease. Thus, new alternatives of cytotoxic agents combined
with lapatinib might be warranted considering the scenario of
multiple lines of treatment for MBC.
 The present phase II study was designed to assess the efﬁcacy of
L combined with C (standard) and other new combinations such
as with V and G in HER2þ MBC progressing after taxane.
 Our study results have shown that LV and LG seem to be active
combinations in patients with HER2þ MBC after taxane failure.Acknowledgments
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